Therapeutic Indications

Bortezomib is indicated for:

Multiple myeloma

Irrespective of gender only Adults (18 - 65 years old)

Bortezomib as monotherapy or in combination with pegylated liposomal doxorubicin or dexamethasone is indicated for the treatment of adult patients with progressive multiple myeloma who have received at least 1 prior therapy and who have already undergone or are unsuitable for

haematopoietic stem cell transplantation. Bortezomib in combination with melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.

Bortezomib in combination with dexamethasone, or with dexamethasone and thalidomide, is indicated for the induction treatment of adult patients with previously untreated multiple myeloma who are eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Intravenous - 1.3 mg/m² twice a wek for 2 weeks

Treatment 2: Subcutaneous - 1.3 mg/m² twice a wek for 2 weeks

Mantle cell lymphoma

Irrespective of gender only Adults (18 - 65 years old)

Bortezomib in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Intravenous - 1.3 mg/m² twice a wek for 2 weeks